Longevity Digest, September 13–20: a GLP-1 lifespan result in mice, the 8-gram LDL rule, and 14 dementia risk factors
Attia and Sinclair read the same semaglutide mouse study two different ways, Attia's guest makes the case for watching LDL from age 30, and Blueprint and Rhonda Patrick supply thresholds a reader can measure this week.
This digest covers the public output of Peter Attia, David Sinclair, Bryan Johnson's Blueprint team, and Rhonda Patrick between September 13 and September 20, 2026, Pacific Time. One preclinical study of semaglutide shaped the week: Peter Attia analyzed it in full on September 19, David Sinclair shared a Lifespan Magazine explainer of the same paper the next day, and the two readings land in different places. Around that result, Attia made the case for lowering LDL decades before symptoms appear, Blueprint published a dementia risk-factor list and a cocoa page, and Rhonda Patrick posted four separate items on multivitamins, post-lifting heat, vitamin D, and plastic clearance.
The week in one screen
| Figure | Focus this week | Primary evidence tier | Actionable takeaway |
|---|---|---|---|
| Peter Attia | Semaglutide and mouse lifespan 12; cumulative LDL exposure 3 | A mouse lifespan study with a calorie-restriction comparison; a clinician interview over genetic and trial data | Median lifespan rose 12% in female mice treated from 20 months, and the short-lived control group decides how far that travels; separately, a lifetime LDL below 80 mg/dL is the threshold his guest uses 13 |
| Bryan Johnson / Blueprint | Fourteen modifiable dementia risk factors 4; cocoa flavanols and heavy metals 5 | Company content: an epidemiology-derived risk-factor list, and a product-education page | Pick one factor to work on this week, from 150 minutes of weekly aerobic activity to a systolic blood pressure target of 120 mmHg from age 40 4 |
| Rhonda Patrick | Multivitamins and metabolomic aging clocks 6; heat after lifting 7; vitamin D with abdominal obesity 8; plastic clearance 9 | A secondary analysis of a randomized trial, a cohort study, a summary of a meta-analysis, and a mechanistic roundup | The multivitamin clock shifts did not survive correction for multiple testing; abdominal obesity with deficient vitamin D carried 123% higher all-cause mortality in adults 50 and older 8 |
| David Sinclair | GLP-1 drugs as longevity drugs 10; fructose in juice 11 | A magazine explainer he shared, built on mouse and human trial data | Lifespan treats GLP-1 drugs as serious longevity candidates while asking for human lifespan data; a glass of juice carries 12 to 18 g of fructose equivalents 11 |
Peter Attia: semaglutide in mice, and the control group that decides the reading
Peter Attia, the physician who founded the Early Medical practice and hosts The Peter Attia Drive, published "Can semaglutide slow aging?" on September 19 with Lauren Fritsch and Michael Rae 1. The article works through a mouse study published in Nature on September 2 by Yufan Feng and colleagues, in which 20-month-old female C57BL/6 mice received daily subcutaneous semaglutide at 10 nmol/kg, a dose chosen to produce clinically relevant human exposure, and 40 treated animals and 39 controls were followed until death 2.
Median lifespan reached 834 days in treated mice against 742 days in controls, a 12% increase. Deaths were distributed across the same categories of age-related decline in both groups, which is the pattern a drug that slows aging broadly would produce. Treated mice ate about 24% less and lost fat while keeping lean tissue. Smaller three-month cohorts performed better on spatial memory, exploratory behaviour, motor coordination, endurance, and glucose tolerance, even after adjustment for body weight, and their tissue carried more markers of hippocampal neurogenesis and fewer inflammatory cytokine and senescence markers 1.
Attia's decisive caveat concerns the controls. A median of 742 days runs short for this strain: female mice of the same strain reached 866 days in a large Jackson Laboratory study. Substrain, diet, housing, and handling all move mouse lifespan, so cross-study comparisons carry their own error. The gap still leaves a second reading standing, in which semaglutide offset something specific to this cohort rather than slowing aging itself. Replication in an independent colony with more typical control survival, in males as well as females, plus a calorie-matched lifespan arm, are the experiments that would settle it 1.
The calorie restriction comparison was run separately and gave a partial answer. Mice cut to 24% fewer calories lost comparable weight and fat and matched the semaglutide group on movement and endurance. Semaglutide-treated mice did better on spatial memory, exploratory drive, and glucose control, and several of their measures improved relative to their own baseline while the restricted mice held theirs. The Berkeley-led team concluded that GLP-1 receptor activation behaves as a calorie restriction mimetic with effects beyond reduced intake 12.
One strain of female mice, treated under controlled laboratory conditions, is the whole of the lifespan evidence. No human trial has tested semaglutide against death as an endpoint; the human trials that exist measure disease events. A reader can track the result and wait for replication, and the article gives no basis for changing a prescription over it 1.
What Attia's guest says about the timing of LDL
On September 14, Attia released episode #407 with Michael Davidson, M.D., a cardiologist and lipidologist who directs the Lipid Clinic at the University of Chicago and is the chief executive of NewAmsterdam Pharma 3. Davidson's argument is that prevention should target the causal driver of atherosclerotic disease rather than a ten-year risk score, and he carries an arithmetic figure for it: about 8 grams of cumulative LDL cholesterol exposure over a lifetime produces heart disease. That total arrives the same way at 200 mg/dL for 40 years, at 100 mg/dL for 80 years, or at 80 mg/dL for 100 years. Keep LDL below 80 mg/dL throughout life, he says, and heart disease stays rare 3.
Most of the episode follows the drug he is developing. Obicetrapib is a CETP inhibitor, the fifth attempt at a class that failed four times: torcetrapib from Pfizer, dalcetrapib from Roche, and evacetrapib from Lilly all collapsed, and Merck's REVEAL trial added its own lessons. Davidson walks through the phase 2 and phase 3 program — ROSE, BROOKLYN, BROADWAY, and TANDEM — and the PREVAIL outcomes trial that will decide whether the reductions in LDL cholesterol, apoB, LDL particle number, and Lp(a) translate into fewer cardiovascular events. He and Attia then move into APOE4 and Alzheimer's disease, where the CETP mechanism and the p-tau 217 biomarker data from BROADWAY are the open questions, and into omega-3 fatty acids, including the difficulty of delivering DHA to the brain 3.
The part a reader can use sits in the first half. Davidson started a statin as soon as one existed; his brother, a family physician who became a strict vegetarian and delayed medication, needed a bypass at 44. He offers that N-of-1 comparison as the case for paying attention in the 30-to-40 decade, when plaque forms fastest and an effective therapy has the most years to work. Obicetrapib is investigational, its class has four clinical failures behind it, and its outcomes trial has yet to report 3.
Blueprint: a dementia risk-factor checklist, and a cocoa label
Blueprint, Bryan Johnson's protocol company, published two articles in the window, both by Vanessa Gibbs. Both are company content, which makes the numbers on the page useful as specifications and the framing worth separating from the evidence.
"14 Brain Health Protocols" appeared on September 18 and organises the modifiable risk factors for dementia, a set epidemiologists estimate could prevent or delay up to 45% of cases 4. Each factor arrives with a threshold a reader can measure:
- Physical inactivity: 150 minutes of moderate or 75 minutes of vigorous aerobic activity each week, extended to six hours where the schedule allows.
- Alcohol: 12 drinks or fewer per week, with Johnson abstaining.
- Air pollution: an indoor monitor placed in a breathing zone, a HEPA purifier running overnight in the bedroom, a MERV 13 filter where the system takes one, and shorter outings when the Air Quality Index passes 150.
- Hearing loss: ear protection at 80 decibels and above, and hearing aids as soon as they help. The article links untreated hearing loss to 30 to 40% faster brain shrinkage.
- High LDL cholesterol: regular testing, a heart-healthy diet, and cholesterol-lowering medication where a clinician prescribes it.
- High blood pressure: a systolic target of 120 mmHg or below from age 40. Blueprint calls blood-pressure medication the only proven preventative medication for dementia.
- Obesity: a waist-to-height ratio of 0.5 or lower, found by dividing waist circumference by height.
- The remaining factors — smoking, limited social contact, vision loss, depression, diabetes, head injury, and low mental stimulation — follow the same shape, one measurable lever each.
The thresholds are the useful half, because most of them are things a reader can check this week. The list itself restates a risk-factor taxonomy that public-health bodies assembled, and attaching a protocol to each factor is Blueprint's editorial work rather than a trial result 4.
The second article, from September 15, covers cocoa. It argues that cocoa flavanols support vascular function, blood pressure, cholesterol, blood sugar, and cognitive performance, then turns to quality: dutching, an alkalinization step in chocolate manufacturing, removes about 60% of the flavonoids, and cocoa can carry lead, cadmium, and arsenic. Blueprint names its own product's specification against those criteria — 8% flavanols, more than 400 mg per serving, undutched, third-party tested for heavy metals — and closes with a Food and Drug Administration disclaimer stating the product is not intended to diagnose, treat, cure, or prevent any disease 5. The flavanol mechanism rests on a real literature; the percentage belongs to a product label.
Bryan Johnson published nothing on his own protocols, supplement doses, or measurements during the window.
Rhonda Patrick: four studies, four boundaries
Rhonda Patrick, a biomedical scientist who hosts FoundMyFitness, posted four items between September 15 and September 18. Each summarises a study, and each comes with her own statement of what the study can carry.
Multivitamins and metabolomic aging clocks. On September 16 she described a secondary analysis of the COSMOS trial, published in GeroScience in March 2026, that followed 399 participants with an average age of 70 through two years of a daily multivitamin or placebo 612. The multivitamin raised DHA and omega-3 concentrations, delayed the rise in creatinine, shifted seven metabolomic aging clocks in a younger direction by somewhere between half a year and a year, and lowered metabolomic risk scores for 16 conditions including major cardiovascular events, kidney disease, dementia, cataracts, glaucoma, liver disease, non-melanoma skin cancer, and prostate cancer. Patrick flagged the ceiling in the same post: the effects reached nominal significance only, and none survived correction for multiple testing. The risk scores are molecular signatures, and clinical disease events were never the endpoint 612.
Heat after lifting. On September 17 Patrick wrote about passive heat exposure after resistance training as a possible aid to muscle growth, citing a meta-analysis she credits to Brad Schoenfeld, an exercise scientist who studies hypertrophic adaptation 7. Her mechanism: heat is a cellular stressor, and whole-body heating after exercise raises heat-shock protein expression and activates mTOR signalling. Her current practice is about 20 minutes in a 180 °F sauna after lifting, done for the muscle adaptation alongside the cardiovascular and brain-health effects of sauna use. She described the evidence as inconclusive in the post itself. A 2026 Delphi consensus paper in the European Journal of Applied Physiology reached for agreement on passive heating's dosing and safety parameters precisely because protocols are inconsistent and the dose-response unsettled 13. For a reader already training, the sauna sits in the low-cost addition column until the hypertrophy signal firms up.
Vitamin D status with abdominal obesity. On September 18 she shared findings from the English Longitudinal Study of Ageing on adults aged 50 and older 814. Measured against adults with neither risk factor, all-cause mortality was 47% higher with abdominal obesity and sufficient vitamin D, 50% higher with abdominal obesity and insufficient vitamin D, and 123% higher with abdominal obesity and deficient vitamin D. Patrick read the pattern as vitamin D status mattering more in people carrying excess abdominal fat, and noted the observational design, which leaves open whether correcting a deficiency removes the excess risk 8.
Clearing microplastics and PFAS. On September 15 Patrick returned to microplastics and the chemicals that travel with them, with exposure reduction first and three strategies for supporting the body's own clearance systems 9. Dietary fibre adds bulk and may trap particles, limiting their reabsorption and increasing faecal elimination. Sulforaphane activates the NRF2 pathway, which turns on phase 2 detoxification enzymes. Oat beta-glucan may interrupt the recycling of PFAS between the liver and the gut. Blood-filtering procedures such as apheresis appear in the post as an invasive and expensive medical option. She labelled all three dietary strategies promising with limited human evidence behind them 9.
David Sinclair: sharing the GLP-1 case, and a warning about juice
David Sinclair is a professor of genetics at Harvard Medical School and the host of Lifespan. He posted twice in the window on matters a reader can weigh.
On September 20 Sinclair shared a Lifespan Magazine explainer titled "Semaglutide and the Longevity Question" by Dr. Kelly Rich, M.S., C.G.C., Ph.D., a genetic counsellor on the magazine's staff 1015. The page carries a September 8 date, so the article precedes the week and the share is the new event. It covers the same Nature paper and adds an interview with Danica Chen, the professor of metabolic biology at the University of California, Berkeley who led the study. Chen said her group expected the drug to behave like calorie restriction and was surprised that it did better on spatial memory, exploratory drive, and glucose metabolism, with some measures improving above the animals' own baseline. She described that as reversing age-related decline rather than slowing it 15.
The article also assembles the human evidence around GLP-1 drugs. A Veterans Affairs analysis of more than 200,000 people associated GLP-1 receptor agonist use with lower risks of cardiometabolic disease, neurocognitive disorders including Alzheimer's disease and dementia, coagulation disorders, and infectious illness. In the SELECT trial, more than 17,000 adults with overweight or obesity, established cardiovascular disease, and no diabetes received weekly semaglutide or placebo, and major cardiovascular events fell by 20% over roughly three years, with a lower risk of death from any cause. Both findings are real, and neither trial was designed to test aging 15.
The article's own list of limits runs long: female mice only, one strain, daily dosing under tightly controlled conditions, gastrointestinal side effects that can be substantial, women losing somewhat more weight than men, and the risk that weight lost in old age takes lean tissue with it. Its conclusion is that stamping semaglutide as a bona fide anti-aging drug now would be premature, and that the result is correspondingly hard to dismiss 15.
Later the same day, Sinclair posted about orange juice: a glass carries 12 to 18 grams of fructose equivalents, and he tied that load to liver lipogenesis and fatty liver, higher triglycerides and VLDL, hepatic insulin resistance, uric acid production, and visceral fat accumulation 11. The post is his comment on another account's complaint about morning juice, and the mechanism list is the established case against liquid fructose rather than a new experimental result.
Cross-expert check: two readings of one mouse study
Semaglutide produced the week's only same-intervention comparison. Attia and Lifespan Magazine reached the same Nature paper within about a day, and they agree on the shape of the caveats: female mice only, a single strain, daily injections under controlled conditions, gastrointestinal side effects, and the risk of losing lean tissue in older adults. They agree as well that the control animals' 742-day median runs short for the strain 115.
They part company on what that short median costs the result. Attia puts it at the centre and keeps cohort-specific survival open as an alternative explanation, which is why he asks for replication in an independent colony before anyone calls the effect geroprotection. The Lifespan piece argues that no single agreed normal lifespan exists for laboratory mice, that 742 days sits inside the published range, and that the soundest comparison stays the treated and control animals raised under the same roof — the one this experiment made. Lifespan lands on GLP-1 drugs as serious longevity candidates; Attia lands on a compelling reason to take the possibility seriously and wait 115.
A second pattern is methodological, and it belongs in the reader's own reasoning. Davidson's LDL threshold and Patrick's vitamin D figures both rest on cumulative exposure measured in large observational or genetic datasets, and in both cases the intervention being recommended has yet to be tested as an intervention in that exact group. The same arithmetic cuts the other way in the semaglutide debate, where a single cohort's baseline survival changes what the trial result means. Reading the comparison group is the skill all three items ask for 38.
What to carry forward
- Treat the semaglutide lifespan result as a mouse result. One strain, one sex, one laboratory. Replication in males and in an independent colony is the next evidence milestone, and no human trial has used death as an endpoint 115.
- Know your LDL number and get it early. A lifetime below 80 mg/dL is the threshold Davidson uses to describe a life free of heart disease, and the argument starts in the 30s, when plaque forms fastest 3.
- Measure the brain-health items you can measure this week. Waist-to-height ratio, resting blood pressure, hearing, and the air in the room where you sleep each have a number attached 4.
- Weigh the multivitamin finding by its correction for multiple testing. The clock shifts sit below that line, so this stays a hypothesis about a cheap daily habit 612.
- Keep the sauna after training where it belongs. About 20 minutes at 180 °F after lifting is cheap for most people; the hypertrophy claim waits on better data, and training volume still does the work 713.
- Read abdominal fat and vitamin D together, and read both as a risk marker. Correcting a deficiency may or may not move the mortality figure, and that trial has yet to run 814.
- Reduce plastic exposure first, then consider fibre, sulforaphane, and oat beta-glucan. All three clearance strategies rest on limited human evidence 9.
References
- 1Can semaglutide slow aging?
peterattiamd.com
- 2
- 3
- 414 Brain Health Protocols
blueprint.bryanjohnson.co
- 5Cocoa Longevity Benefits
blueprint.bryanjohnson.co
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.